In a bid to lower its costs for hepatitis C medicines, Louisiana officials are exploring a novel approach in which the state would make subscription-based payments to drug makers.
Essentially, the state would agree to pay a fixed amount of money over several years for unlimited access to medication for anyone who is enrolled in the state Medicaid program or incarcerated in a state prison. Some details need to be worked out, but payments to one or more companies would be equal to or less than what the state is currently spending to provide hepatitis C medicines to these populations.
About the Author Reprints
